Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.47 |
| ▸ | LDHA | P00338 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.36 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.36 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.36 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.36 |
| ▸ | CBFB | Q13951 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | SULT1A1 | P50225 | 1/20 | 0.36 |
| ▸ | G6PD | P11413 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269955 | 0.84 | EGLN1 (0.69) | EGLN1 | |
| SCHEMBL1270577 | 0.80 | EGLN1 (0.53) | EGLN1 | |
| SCHEMBL1270094 | 0.78 | EGLN1 (0.45) | EGLN1HSD17B10KDM4EKMT2AMAPT | |
| SCHEMBL4869324 | 0.70 | KDM4E (0.54) | LDHARAB9AKDM4EKMT2AMAPT | |
| SCHEMBL1269880 | 0.69 | EGLN1 (0.76) | EGLN1 | |
| SCHEMBL1270027 | 0.68 | EGLN1 (0.71) | EGLN1 | |
| SCHEMBL1270563 | 0.66 | EGLN1 (0.67) | EGLN1MAPT | |
| SCHEMBL1811763 | 0.66 | EGLN1 (0.43) | EGLN1HSD17B10KDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL2636076 | 0.65 | KDM4E (0.55) | LDHAHSD17B10RAB9AKDM4EKMT2A | |
| SCHEMBL12922996 | 0.64 | PFKFB3 (0.53) | LDHAHSD17B10KDM4EKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2011-02-03 | — | — | US | disclosed |
| EP-2188295-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | Crystalgenomics, Inc. (KR) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009037570-A2 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | CRYSTALGENOMICS, INC. (KR) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028507-A1 | PYRIDINE DERIVATIVES AND METHODS OF USE THEREOF | EGLN3, EGLN2, HIF1A | EGLN1 5/4885LDHA 506/4885HSD17B10 659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.